Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
"Special Situation"-Aktie mit Multi-Tenbagger-Potenzial im heißesten Rohstoff-Markt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
338 Leser
Artikel bewerten:
(1)

Vaica to Offer Anticoagulation Medication Adherence & Monitoring solution

TEL AVIV, Israel, April 19, 2021 /PRNewswire/ -- Vaica Medical, an innovation leading provider in medication adherence and remote patient management (RPM) is announcing its anti-coagulation (blood clotting) remote management solution.

The Vaica Medy provides a seamless workflow for monitoring vital signs as well as medication adherence for patients from the comfort of their own home

The need to maintain an optimal blood viscosity levels is pertinent for at-risk patients with Thrombotic Predisposition (hypercoagulable states), heart rhythm disorders, artificial heart valves, Renal failure, and more. In the US alone, 1% of the adult population are on blood thinners. A commonly prescribed (and affordable) medication is Warfarin. However, the use of Warfarin requires life-long and frequent blood testing of INR (blood-thinning level) to optimize the dosage and ensure that the INR remains within the patient-specific therapeutic range. This current standard of care requires frequent laboratory and doctor visits, which in many cases deters patients and cause them not to adhere to their treatment regimen- a life-threatening situation.

Vaica's comprehensive 360? "Track and Treat" approach provides all necessary tools to successfully address these challenges. The basic Anticoagulation kit includes Vaica's SimpleMed Smart Medication adherence dispenser, along with a home Coagulometer. Patients will be reminded daily to take their medication, and periodically to measure their INR. The physician shall receive all the information necessary to resolve of out-of-therapeutic-range results. This unique platform will markedly reduce the need for patients' laboratory and doctor office visits, and most importantly, will ensure that patients remain within their target therapeutic range, thus minimizing the risks of life-threatening hemorrhagic or thromboembolic complications.

"Vaica's seamless solution, far exceeding today's standard-of-care, provides an effective means to successfully tackle a serious problem," said Eran Steinberg, Vaica's President. "Smart management of blood thinning is yet another consequential and innovative offering from Vaica"

The data generated by Vaica's Anticoagulation Kit, integrating electronic medication dispenser for optimizing Warfarin adherence with home coagulometer, is seamlessly aggregated by the Medy home hub and uploaded via cellular connectivity to the secure Vaica cloud infrastructure. The entire workflow is reimbursable by the major US insurance agencies using existing CPT codes.

For more Information, please refer to https://www.vaica.com/medy-rpm/

About Vaica

Vaica Medical (www.vaica.com) is a leading Telemedicine Company positioned in the nexus of Remote Patient Monitoring Platform (RPM) coupled with Smart Medication Adherence IoT Devices for increasing patient engagement, persistence and well-being.

Company Contact:

Noa Lapidot
Business Unit Director
noa.lapidot@vaica.com

Photo - https://mma.prnewswire.com/media/1490795/Vaica_Medical.jpg

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.